ES2323845T3 - Secuencias genomicas de neisseria y procedimientos de uso. - Google Patents

Secuencias genomicas de neisseria y procedimientos de uso. Download PDF

Info

Publication number
ES2323845T3
ES2323845T3 ES00910392T ES00910392T ES2323845T3 ES 2323845 T3 ES2323845 T3 ES 2323845T3 ES 00910392 T ES00910392 T ES 00910392T ES 00910392 T ES00910392 T ES 00910392T ES 2323845 T3 ES2323845 T3 ES 2323845T3
Authority
ES
Spain
Prior art keywords
sequence
protein
orf
sequences
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00910392T
Other languages
English (en)
Spanish (es)
Inventor
Mariagrazia Pizza
Erin Hickey
Jeremy Peterson
Herve Tettelin
J. Craig Venter
Vega Masignani
Cesira Galeotti
Marirosa Mora
Giulio Ratti
Maria Scarselli
Vincenzo Scarlato
Rino Rappuoli
Claire M. Frazer
Guido Grandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
J Craig Venter Institute Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
J Craig Venter Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/023573 external-priority patent/WO2000022430A2/en
Priority claimed from GB0004695A external-priority patent/GB0004695D0/en
Application filed by Novartis Vaccines and Diagnostics Inc, J Craig Venter Institute Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of ES2323845T3 publication Critical patent/ES2323845T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES00910392T 1999-04-30 2000-03-08 Secuencias genomicas de neisseria y procedimientos de uso. Expired - Lifetime ES2323845T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13206899P 1999-04-30 1999-04-30
US132068P 1999-04-30
PCT/US1999/023573 WO2000022430A2 (en) 1998-10-09 1999-10-08 Neisseria genomic sequences and methods of their use
WOUS99/23573 1999-10-08
GB0004695A GB0004695D0 (en) 2000-02-28 2000-02-28 Protein expression
GB0004695 2000-02-28

Publications (1)

Publication Number Publication Date
ES2323845T3 true ES2323845T3 (es) 2009-07-27

Family

ID=27255563

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00910392T Expired - Lifetime ES2323845T3 (es) 1999-04-30 2000-03-08 Secuencias genomicas de neisseria y procedimientos de uso.

Country Status (13)

Country Link
US (1) US20070219347A1 (https=)
EP (2) EP1605061A1 (https=)
JP (1) JP2003527079A (https=)
CN (2) CN101033467A (https=)
AT (1) ATE430207T1 (https=)
AU (1) AU780308B2 (https=)
BR (1) BR0010361A (https=)
CA (1) CA2371032A1 (https=)
DE (1) DE60042114D1 (https=)
DK (1) DK1185691T3 (https=)
ES (1) ES2323845T3 (https=)
MX (1) MXPA01011047A (https=)
WO (1) WO2000066791A1 (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
CA2360667A1 (en) 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Neisseria meningitidis basb054 polypeptides and encoding polynucleotides and uses thereof
CA2365102A1 (en) 1999-03-12 2000-09-21 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides and encoding polynucleotides and uses thereof
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ.ピー.アー. 保存されたナイセリア抗原
EP2270173B1 (en) 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Combination neisserial compositions
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
PL216780B1 (pl) 2000-01-25 2014-05-30 Univ Queensland Of Santa Lucia Wyizolowane białka zawierające konserwatywne obszary antygenu powierzchniowego NhhA z Neisseria meningitidis, białka fuzyjne, kompozycja farmaceutyczna, przeciwciało monoklonalne lub wiążący antygen fragment przeciwciała monoklonalnego, wyizolowany kwas nukleinowy, konstrukt ekspresyjny, komórka gospodarza, sposób wytwarzania rekombinowanego białka, sposób wykrywania N. meningitidis w próbce biologicznej, sposób diagnozowania zakażenia N. meningitidis oraz sposób wykrywania N. meningitidis w próbce biologicznej uzyskanej od pacjenta oraz zastosowanie wyizolowanego białka, białka fuzyjnego i konstruktu ekspresyjnego
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0107219D0 (en) * 2001-03-22 2001-05-16 Microbiological Res Authority Immunogenic commensal neisseria sequences
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
CN1306956C (zh) * 2001-04-17 2007-03-28 希龙公司 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
RU2355704C2 (ru) * 2001-04-17 2009-05-20 Новартис Вэксинс Энд Диагностикс, Инк Моноклональное антитело, направленное против gna33 пептида, и его применение
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
BR0211494A (pt) 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1495039A4 (en) * 2002-03-20 2006-07-26 Univ Emory MUTANTS OF NEISSERIA, LIPOOLIGOSACCHARIDES AND IMMUNOGENIC COMPOSITIONS
EP1524991A1 (en) * 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
CU23237A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
AU2006220772A1 (en) * 2005-03-04 2006-09-14 Verenium Corporation Nucleic acids and proteins and methods for making and using them
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
CA2656474A1 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
WO2010130896A2 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 rLP2086 항원의 안정한 제제
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3622080B1 (en) * 2017-05-10 2024-03-27 Global Bioenergies Improved methods for producing isobutene from 3-methylcrotonic acid
BR112020001255A2 (pt) 2017-07-21 2020-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services composições imunogênicas de neisseria meningitidis
US20220081707A1 (en) * 2018-07-25 2022-03-17 The Trustees Of Indiana University Diagnostic assay for a strain of neisseria meningitidis
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN113136444B (zh) * 2021-05-10 2024-04-19 临沂大学 医用食品中海氏肠球菌的微滴数字pcr检测方法
CN116162140B (zh) * 2022-07-19 2025-09-09 四川大学华西医院 一种幽门螺杆菌重组抗原蛋白SecG及其制备方法与应用
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
CN119792505A (zh) * 2023-10-10 2025-04-11 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE912559A1 (en) * 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
CA2047043A1 (en) * 1990-07-19 1992-01-20 Allen I. Oliff Class ii protein of the outer membrane of neisseria meningitidis having immune enhancement properties
NZ238974A (en) * 1990-07-19 1992-12-23 Merck & Co Inc Vaccine comprising the class ii major immuno-enhancing protein of the outer membrane of neisseria meningitidis covalently coupled to an antigen-specific composition of one such conjugate
AU5426098A (en) * 1996-10-24 1998-05-15 Emory University Invasion associated genes from (neisseria meningitidis) serogroup
BR9914374A (pt) * 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso

Also Published As

Publication number Publication date
MXPA01011047A (es) 2003-10-14
US20070219347A1 (en) 2007-09-20
JP2003527079A (ja) 2003-09-16
AU3249200A (en) 2000-11-17
EP1605061A1 (en) 2005-12-14
CN101033467A (zh) 2007-09-12
WO2000066791A1 (en) 2000-11-09
DE60042114D1 (de) 2009-06-10
CN1359426A (zh) 2002-07-17
BR0010361A (pt) 2003-06-10
EP1185691A1 (en) 2002-03-13
DK1185691T3 (da) 2009-06-22
AU780308B2 (en) 2005-03-17
ATE430207T1 (de) 2009-05-15
CA2371032A1 (en) 2000-11-09
EP1185691B1 (en) 2009-04-29

Similar Documents

Publication Publication Date Title
ES2323845T3 (es) Secuencias genomicas de neisseria y procedimientos de uso.
ES2294629T3 (es) Antigenos de neisseria y composiciones.
ES2333071T3 (es) Antigenos de neisseria meningitidis.
EP1559795A2 (en) Neisseria genomic sequences and methods of their use
US20070026021A1 (en) Neisseria meningitidis antigens and compositions
AU2012203235B2 (en) Neisseria meningitidis antigens and compositions